Overview: Flow Cytometry CD19 Panel
Introduction: The Flow Cytometry CD19 Panel is a diagnostic tool designed to assess B-cell population using whole blood samples. In India, B-cell disorders (CLL, B-ALL, lymphomas) affect thousands annually, with CD19 as a key pan-B-cell marker for enumeration and characterization in immunophenotyping. High morbidity from under-testing in rural/low-SES patients with lymphocytosis or lymphadenopathy, limited flow cytometry labs, delayed diagnosis leading to progression or inappropriate therapy. Per hematology/immunology practices aligned with ICMR and Indian Society of Hematology guidelines, the test employs flow cytometry for CD19+ cell count, total lymphocytes, and B-cell profile over 1-2 days with high accuracy, valuable for leukemia/lymphoma diagnosis and monitoring. This diagnostic falls under immune profiling and targets patients with suspected B-cell malignancy or immunodeficiency, addressing accurate detection to guide targeted therapy (rituximab) or transplant. With elevated morbidity due to under-testing, the test supports public health efforts by enabling precise immunophenotyping and improving outcomes. Its whole blood-based approach ensures reliable B-cell analysis.
Other Names: Flow CD19 Pnl.
FDA Status: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.
Historical Milestone: CD19 flow standard; in India, used in leukemia protocols.
Purpose: The test assesses 3 parameters including CD19+ cell count to guide B-cell population evaluation, detect abnormalities, inform management.
Test Parameters: 1. CD19+ Cell Count, 2. Total Lymphocytes, 3. B-Cell Profile.
Pretest Condition: No fasting required; patients should have suspected B-cell disorder.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow).
Medical History: Patients should provide details on lymphocytosis, lymphadenopathy, prior therapy.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed B-cell disorder including progression, benefits of profiling, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low lymphocyte count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal CD19+ population indicates B-cell disorder, necessitating specialist input. Normal may require follow-up.
Specialist Consultation: Hematologists/immunologists should be consulted for management.
Additional Supporting Tests: Full immunophenotyping, bone marrow biopsy for confirmation.
Test Limitations: Requires viable cells; comprehensive approach required.
References: Indian Journal of Hematology 2024, Flow Studies India 2023.
